A Study to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract and Aspirin in Diabetic Peripheral Angiopathy.
Diabetic Peripheral Angiopathy
About this trial
This is an interventional treatment trial for Diabetic Peripheral Angiopathy
Eligibility Criteria
<Inclusion Criteria> Male or female aged between 20 years and 75 years(inclusive) Patients who diagnosed as type 2 diabetes and diabetic peripheral angiopathy Patients with a maximum intra-carotid membrane thickness (maximum IMT) of 0.9 mm or more among the thickest areas, including plaques, in the CCA, ICA, and Bulb three areas of the carotid artery <Exclusion Criteria> Patients who diagnosed with type 1 diabetes, secondary diabetes, or gestational diabetes Patients with cerebrovascular or cardiovascular complications within 6 months of screening (cerebral infarction, transient ischemic seizures, myocardial infarction, unstable angina, coronary artery bypass graft(CABG), PCI, etc.) Patients with bleeding (hemophilia, capillary weakness, intracranial hemorrhage, upper digestive tract hemorrhage, urinary tract hemorrhage, hematopoietic hemorrhage, active digestive ulcers, etc.) or peptic ulcers within 3 months of screening Patient who took anticoagulants, antiplatelet drugs including aspirin, cilostazol, thrombolytic agents, prostaglandin E1 and glucagon-like peptide -1 (GLP-1) receptor agonist within 2 weeks of the baseline
Sites / Locations
- SK chemicalsRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Renexin CR 200/160mg
Aspirin 100mg
Single oral administration of Renexin CR 200/160mg, QD
Single oral administration of Aspirin 100mg, QD